Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU)

Description

This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe chronic spontaneous urticaria (CSU).

Conditions

Chronic Spontaneous Urticaria

Talk to us

Study Overview

On this page

Study Details

Study overview

This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe chronic spontaneous urticaria (CSU).

A Randomized, Double-Blind, Placebo Controlled, Dose-Ranging Study Evaluating the Efficacy and Safety of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria

Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU)

Condition
Chronic Spontaneous Urticaria
Intervention / Treatment

-

Contacts and Locations

Birmingham

Cahaba Dermatology Skin Health Center, Birmingham, Alabama, United States, 35244

Mobile

Velocity Clinical Research, Mobile, Mobile, Alabama, United States, 36608

Fremont

Center for Dermatology Clinical Research, Fremont, California, United States, 94538

Lancaster

Antelope Valley Clinical Trials, Lancaster, California, United States, 93534

Northridge

Northridge Clinical Trials, Northridge, California, United States, 91325

Upland

Integrated Research of Inland, Upland, California, United States, 91786

Ventura

FOMAT Medical Research, Ventura, California, United States, 93003

Fort Myers

AMR Fort Myers, Fort Myers, Florida, United States, 33912

Plainfield

The Indiana Clinical Trials Center, Plainfield, Indiana, United States, 46168

Lexington

Bluegrass Allergy Care, Lexington, Kentucky, United States, 40509

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Confirmed CSU diagnosis for at least 3 months with an inadequate response to H1-antihistamines.
  • * Subjects who are taking H1-antihistamines must be on a stable regimen 4 weeks prior to Day 1 and while on study.
  • * Urticaria Activity Score (UAS7) equal to or greater than 16 at Day 1. UAS entries must be completed for a minimum of 4 out of the 7 days prior to Day 1.
  • * Any clinically significant abnormality in laboratory evaluations, physical examinations, vital signs, or ECG at Screening, according to the Investigator's discretion.
  • * Use of certain medications.
  • * History of diseases with urticaria or angioedema symptoms, other than CSU and symptomatic dermographism.
  • * Significant medical history other than CSU, or any other condition which might interfere with the evaluation of CSU.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Evommune, Inc.,

Study Record Dates

2026-05